These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prolonged jaundice following percutaneous coronary intervention and ticlopidine therapy.
    Author: Tsui PT, Lai ST, Leung WS, Mok NS, Wu CW, Lau ST, Choi YC.
    Journal: Hong Kong Med J; 2002 Feb; 8(1):57-9. PubMed ID: 11861996.
    Abstract:
    Ticlopidine, an adenosine diphosphate receptor blocker, is widely used to prevent subacute stent thrombosis after percutaneous coronary intervention. Along with neutropenia and thrombotic thrombocytopenic purpura, cholestatic hepatitis is one of the most serious potential side-effects of ticlopidine therapy. Four patients with prolonged jaundice after ticlopidine therapy, including one fatal case, are presented. Alternative antithrombotic therapy for subsequent percutaneous coronary intervention is also described. Clopidogrel therapy was found to be safe and effective in two patients with a history of ticlopidine-related cholestatic hepatitis.
    [Abstract] [Full Text] [Related] [New Search]